Amin Jamal
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1902973183
Payments from drug & device makers
Across 477 payments — averaging $455.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$163K
- Lilly USA, LLC$50K
- Merz North America, Inc.$574
- Novo Nordisk$419
- IBSA Pharma Inc.$361
- Mannkind Corporation$354
- plus $2K from 28 others
What the payments were for
- Consulting fees$3,5752%
- Speaking & faculty fees$202,80093%
- Travel & lodging$2,8401%
- Food & beverage$7,9174%
- Education$700%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 212 | $163,052 |
| Lilly USA, LLC | 92 | $50,139 |
| Merz North America, Inc. | 3 | $574 |
| Novo Nordisk | 17 | $419 |
| IBSA Pharma Inc. | 32 | $361 |
| Mannkind Corporation | 26 | $354 |
| Dexcom, Inc. | 13 | $311 |
| Abbott | 12 | $243 |
| Medtronic(2 entities) | 18 | $230 |
| Bayer | 3 | $173 |
| Sanofi-aventis U.S. LLC | 7 | $143 |
| Corcept Therapeutics | 1 | $125 |
| Medicure Pharma Inc. | 2 | $125 |
| Lexicon Pharmaceuticals, Inc. | 1 | $122 |
| Amarin Pharma, Inc. | 1 | $115 |
| Amgen(2 entities) | 5 | $110 |
| AstraZeneca(2 entities) | 4 | $108 |
| Echosens North America, Inc. | 2 | $105 |
| Insulet Corporation | 4 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Novartis | 2 | $43 |
| AbbVie | 2 | $42 |
| BD | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Cequr Corporation | 1 | $20 |
| Pfizer | 1 | $19 |
| Lifescan, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Embecta Corp. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$217,262 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 205 | $275,380 |
| OzempicSemaglutide | 92 | $167,732 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $112,827 |
| FarxigaDapagliflozin Propanediol | 96 | $112,560 |
| TradjentaLinagliptin | 91 | $112,499 |
| MounjaroTirzepatide | 66 | $110,298 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $66,434 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 60 | $55,439 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $53,687 |
| ProliaDenosumab | 27 | $45,495 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $41,444 |
| Humalog Kwikpen U-100Insulin Lispro | 109 | $37,239 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 143 | $34,415 |
| VascepaIcosapent Ethyl | 39 | $30,241 |
| Novolog FlexpenInsulin Aspart | 89 | $28,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr | $163,052 | $419,981332 claims |
| Novo NordiskOzempic, Novolog | $419 | $174,203103 claims |
| AstraZenecaFarxiga | $108 | $112,56096 claims |
| Lilly USA, LLCMounjaro | $50,139 | $110,29866 claims |
| AmgenProlia | $110 | $45,49527 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $8,964777 claims |
| AbbVieSynthroid, Armour Thyroid | $42 | $5,87497 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Maria CabanillasHouston$16.4M
- Damaris VegaHouston$12.3M
- Amer Al KaradshehHouston$8.8M
- Amir HassanHouston$5.2M
- Camilo JimenezHouston$5M
- Rocio HarbisonHouston$3.2M
- Gerardo BuesoHouston$1.2M
- Veena WatweHouston$976K
- Andres SplenserHouston$923K
- Prashant KoshyHouston$795K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.